Page 6,614«..1020..6,6136,6146,6156,616..6,6206,630..»

Cambridge Joins Harvard in Opening Stem-Cell Institute

Posted: Published on August 9th, 2012

By Makiko Kitamura - 2012-08-08T23:01:00Z The University of Cambridge will receive 8 million pounds ($12.5 million) to create a new stem- cell research center, joining those established at the University of Oxford and Harvard University. The institute, which will unite 30 research teams, will be funded by the U.K. Medical Research Council and Wellcome Trust, the council said in a statement today. It will eventually be housed in an 8,000 square-meter facility to be constructed at the Cambridge Biomedical Research Campus. Cambridge, England, is home to the largest cluster of biotechnology companies in Europe, according to the statement. Stem cells can reproduce themselves and can develop into any of the 200 or so cell types in the body. They are being explored as possible treatments for conditions such as liver disease, diabetes, blindness, spinal cord injury and neurodegenerative disorders such as Parkinsons disease. Our aim is to close the knowledge gap and drive stem-cell research forward towards clinical applications, Austin Smith, director of the new Wellcome Trust-MRC Cambridge Stem Cell Institute, said in the statement. The world-class facilities will attract the best international talent from the fields of stem-cell biology and regenerative medicine to pursue this goal. Similar research organizations … Continue reading →

Posted in Stem Cell Research | Comments Off on Cambridge Joins Harvard in Opening Stem-Cell Institute

International Stem Cell Corporation to Host Second Quarter 2012 Financial Results Conference Call at 11:00 am ET on …

Posted: Published on August 9th, 2012

CARLSBAD, CA--(Marketwire -08/08/12)- International Stem Cell Corporation (ISCO) http://www.internationalstemcell.com, a California-based biotechnology company focused on therapeutic and research products, announced today that it will host a conference call on Friday, August 10, 2012 at 11:00 am ET to discuss its financial results for the three months ended June 30, 2012. Dr. Simon Craw, Executive Vice President of Business Development, and Ms. Linh Nguyen, Chief Financial Officer, will host the conference call. To attend the call, please use the dial in information below: Date: Friday, August 10, 2012 Time: 11:00 am Eastern Time Conference Line (U.S.): 1-877-317-6776 International Dial-In: 1-412-317-6776 Conference ID: 10017300 Webcast: http://webcast.mzvaluemonitor.com/Home/Login/7fd6c4da-37f0-472c-9f28-cd9eb1b99f87 Please dial in at least 10-minutes before the call to ensure timely participation. A playback replay of the conference call will be available for two weeks following 1 hour after the end of the conference call through end date: Aug 24, 2012 at 9:00 am ET. Teleconference Replay Details: US Domestic: 1-877-344-7529 International: 1-412-317-0088 Conference ID: 10017300 About International Stem Cell Corporation International Stem Cell Corporation is focused on the therapeutic applications of human parthenogenetic stem cells (hpSCs) and the development and commercialization of cell-based research and cosmetic products. ISCO's core technology, parthenogenesis, results in the … Continue reading →

Posted in Stem Cell Research | Comments Off on International Stem Cell Corporation to Host Second Quarter 2012 Financial Results Conference Call at 11:00 am ET on …

Oh, my stars and hexagons! DNA code shapes gold nanoparticles

Posted: Published on August 9th, 2012

ScienceDaily (Aug. 8, 2012) DNA holds the genetic code for all sorts of biological molecules and traits. But University of Illinois researchers have found that DNA's code can similarly shape metallic structures. The team found that DNA segments can direct the shape of gold nanoparticles -- tiny gold crystals that have many applications in medicine, electronics and catalysis. Led by Yi Lu, the Schenck Professor of Chemistry at the U. of I., the team published its surprising findings in the journal Angewandte Chemie. "DNA-encoded nanoparticle synthesis can provide us a facile but novel way to produce nanoparticles with predictable shape and properties," Lu said. "Such a discovery has potential impacts in bio-nanotechnology and applications in our everyday lives such as catalysis, sensing, imaging and medicine." Gold nanoparticles have wide applications in both biology and materials science thanks to their unique physicochemical properties. Properties of a gold nanoparticle are largely determined by its shape and size, so it is critical to be able to tailor the properties of a nanoparticle for a specific application. "We wondered whether different combinations of DNA sequences could constitute 'genetic codes' to direct the nanomaterial synthesis in a way similar to their direction of protein synthesis," … Continue reading →

Comments Off on Oh, my stars and hexagons! DNA code shapes gold nanoparticles

Seattle Genetics Reports Second Quarter 2012 Financial Results

Posted: Published on August 8th, 2012

BOTHELL, Wash.--(BUSINESS WIRE)-- Seattle Genetics, Inc. (SGEN) today reported financial results for the second quarter ended June 30, 2012. The company also highlighted progress with ADCETRIS (brentuximab vedotin) commercialization activities, ongoing and planned clinical trials and upcoming milestones. As the leader in developing antibody-drug conjugate therapies, we along with our many collaborators are using our technology to change the way cancer is treated, said Clay B. Siegall, Ph.D., President and Chief Executive Officer at Seattle Genetics. We remain focused on making ADCETRIS available to patients, and we are delivering on this priority both through continued commercial initiatives for patients in the labeled indications, as well as through our robust clinical development of ADCETRIS in earlier lines of therapy and other CD30-positive malignancies. We are also focused on advancing our robust pipeline of ADC candidates and leveraging our ADC technology in collaborations to further advance the treatment of cancer. Recent ADCETRIS Highlights Other Recent Highlights Upcoming Milestones Second Quarter and First Six Months 2012 Financial Results Revenues in the second quarter of 2012 were $48.8 million, compared to $13.1 million in the second quarter of 2011. Revenues for the six month period ended June 30, 2012 were $97.1 million, compared to … Continue reading →

Posted in FDA Stem Cell Trials | Comments Off on Seattle Genetics Reports Second Quarter 2012 Financial Results

TiGenix Completes Patient Enrollment in Phase IIa Rheumatoid Arthritis Study

Posted: Published on August 8th, 2012

LEUVEN, BELGIUM and MADRID, SPAIN--(Marketwire -08/08/12)- TiGenix (EURONEXT:TIG), the European leader in cell therapy, announced today the completion of patient enrollment in the Company's Phase IIa study of Cx611, a suspension of expanded allogeneic adult stem cells, in rheumatoid arthritis. The Phase IIa clinical trial is a 53-subject, multicenter, placebo-controlled study in 3 cohorts with different dosing regimens, designed to assess safety, feasibility, tolerance, and optimal dosing. The study is being conducted at 23 centers. The Company believes that this clinical trial can set the stage not only for the further development of Cx611 in RA, but also in a wide range of other autoimmune disorders. "In addition to the primary endpoints of safety and optimal dosing, we expect this trial to yield a first indication of the duration of the efficacy of Cx611 in this very difficult patient population: the enrolled patients have previously failed to respond to at least two biologicals," said Eduardo Bravo, CEO of TiGenix. "In the trial patients are treated with three injections of Cx611. The six-month follow-up without further dosing should provide us with a truly meaningful result. This is the most advanced stem cell therapy trial in RA in the world, and completing … Continue reading →

Posted in Mesenchymal Stem Cells | Comments Off on TiGenix Completes Patient Enrollment in Phase IIa Rheumatoid Arthritis Study

TiGenix Completes Patient Enrollment in Phase IIa Rheumatoid Arthritis Study

Posted: Published on August 8th, 2012

LEUVEN, BELGIUM and MADRID, SPAIN--(Marketwire -08/08/12)- TiGenix (EURONEXT:TIG), the European leader in cell therapy, announced today the completion of patient enrollment in the Company's Phase IIa study of Cx611, a suspension of expanded allogeneic adult stem cells, in rheumatoid arthritis. The Phase IIa clinical trial is a 53-subject, multicenter, placebo-controlled study in 3 cohorts with different dosing regimens, designed to assess safety, feasibility, tolerance, and optimal dosing. The study is being conducted at 23 centers. The Company believes that this clinical trial can set the stage not only for the further development of Cx611 in RA, but also in a wide range of other autoimmune disorders. "In addition to the primary endpoints of safety and optimal dosing, we expect this trial to yield a first indication of the duration of the efficacy of Cx611 in this very difficult patient population: the enrolled patients have previously failed to respond to at least two biologicals," said Eduardo Bravo, CEO of TiGenix. "In the trial patients are treated with three injections of Cx611. The six-month follow-up without further dosing should provide us with a truly meaningful result. This is the most advanced stem cell therapy trial in RA in the world, and completing … Continue reading →

Posted in Cell Therapy | Comments Off on TiGenix Completes Patient Enrollment in Phase IIa Rheumatoid Arthritis Study

Charges filed against naturopaths for marijuana prescriptions

Posted: Published on August 8th, 2012

Dimitrios Jimmy Magiasis The state Department of Health has charged two naturopaths with unprofessional conduct for operating an assembly line practice of authorizing medical marijuana at last years Hempfest. The charges, filed Tuesday, appear to be the first disciplinary action taken against a state medical professional for a medical marijuana authorization, said Tim Church, a DOH spokesman. The two naturopaths, Carolyn Lee Bearss and Dimitrios Jimmy Magiasis were featuredin a Seattle Times storylast August in which a reporter received a medical marijuana authorization for $150 at a Hempfest tent. Bearss recommended marijuana as treatment for the reporters lower-back pain without seeing medical records after an appointment that lasted 11 minutes. The naturopaths were independent contractors for a company owned by 4Evergreen Group, one of the largest regional clinics specializing in medical marijuana authorizations. During Hempfest, the two naturopaths saw a combined 216 patients and recommended marijuana for 214 of them, according to the DOH charges againstBearssandMagiasis. The charges accuse the naturopaths of stretching the definition of intractable pain one of the qualifying conditions under the state medical cannabis law and of failing to explore other treatment options, as also required. This assembly line type of practice failed to meet the … Continue reading →

Posted in Prescriptions | Comments Off on Charges filed against naturopaths for marijuana prescriptions

2 face medical discipline for Hempfest pot prescriptions

Posted: Published on August 8th, 2012

Two naturopaths are facing disciplinary action after a weekend of writing medical marijuana authorizations at last year's Hempfest. Carolyn Lee Bearss and Dimitrios "Jimmy" Magiasis were charged Tuesday by the state Department of Health (DOH) with running a medical marijuana "assembly line," writing authorizations at the festival without following the proper standard of care. Between them, the practitioners saw 216 patients at the three-day festival; they sent only two away without an authorization, according to the statement of charges. They are the first Washington medical providers facing disciplinary action in connection with writing marijuana authorizations, according to Tim Church, a spokesman for the DOH. Both naturopaths were working at the festival on contract for a business that owns 4Evergreen Group, a clinic with locations in Seattle and Tacoma. Eric Camm, an attorney for the practitioners, said in a statement that his clients "strongly disagree with the characterizations contained within those allegations," but declined further comment. According to a Seattle Times story written about the festival, 4Evergreen was handing out fliers at the entrance to the marijuana festival advertising authorizations for $200 or $150 for patients who had their medical records with them. Patients watched a short video about Washington's law, … Continue reading →

Posted in Prescriptions | Comments Off on 2 face medical discipline for Hempfest pot prescriptions

Hair-loss drug linked to severe depression in men

Posted: Published on August 8th, 2012

Men who take the hair-loss medication Propecia and develop sexual side effects may be at risk for severe depression and suicidal thoughts, a new study suggests. Don't miss these Health stories We've seen the colorful stripes of tape on the backs of synchronized divers, on the stomachs of beach volleyball players, the legs of track and field stars. But what is it -- and does it really do anything? In the study, 64 percent of men who developed long-lasting sexual side effects from the drug also reported experiencing moderate or severe symptoms of depression, and nearly 40 percent reported suicidal thoughts. Low libido and erectile dysfunction have been reported in men taking Propecia, and in some, the side effects persist after the medication is stopped. It is not known how many men experience long-lasting sexual side effects from Propecia, but it is thought to be a small percentage. Doctors and Propecia users should be aware of the potential serious risks of the medication, "especially as it is being used cosmetically, to alter a normal age-related process," said study researcher Dr. Michael Irwig, an assistant professor of medicine at the George Washington University School of Medicine and Health Sciences in Washington, … Continue reading →

Posted in Drug Side Effects | Comments Off on Hair-loss drug linked to severe depression in men

Grapefruit juice may make low doses of anti-cancer drug as effective as higher doses

Posted: Published on August 8th, 2012

(CBS News) New research finds a simple modification may make a cancer drug three times more powerful without the side effects a higher dose would likely cause. All it takes is a glass of grapefruit juice. In the preliminary study published in the August issue of Clinical Cancer Research, scientists at the University of Chicago set out to analyze how certain foods would affect metabolism of the anti-cancer drug called sirolimus, which is an FDA-approved drug to prevent rejection of a kidney transplant and has been seen to help some people with cancer. The problem with sirolimus, however, is that the drug is easily metabolized and leaves the blood stream before it can show benefits. The optimal dose needed to show anti-tumor benefits also brings with it significant gastrointestinal problems. "Grapefruit juice, and drugs with a similar mechanism, can significantly increase blood levels of many drugs, but this has long been considered an overdose hazard," study director Dr. Ezra Cohen, a cancer specialist at the University of Chicago Medicine, said in a news release. "Instead, we wanted to see if grapefruit juice can be used in a controlled fashion to increase the availability and efficacy of sirolimus." The researchers enrolled … Continue reading →

Posted in Drug Side Effects | Comments Off on Grapefruit juice may make low doses of anti-cancer drug as effective as higher doses

Page 6,614«..1020..6,6136,6146,6156,616..6,6206,630..»